Dr. Reddy's Laboratories Limited (RDY)
$12.82+2.72%Close
BUYRECOVERY · day 18
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $10.7B
- Beta
- 0.25
- Div yield
- 0.67%
- P/E (TTM)
- 30.41
- Short % float
- 3.41%
- Days to cover
- 8.8
- SI change
- -2.0%
- 1W
- +4.06%
- 1M
- +7.73%
- vs SPY 1W
- +3.64%
- vs SPY 1M
- +5.67%
Industry peers
FMP comparable companies · ranked by market cap
- SUNPHARMA.NSSun Pharmaceutical Industries Limited$4.2T$1760.00
- CIPLA.NSCipla Limited$1.1T$1311.30
- MANKIND.NSMankind Pharma Limited$991.2B$2400.00
- TEVABUYTeva Pharmaceutical Industries Limited$47.9BBULLQ 13$41.17+0.17%
- HLNSELLHaleon plc$41.8BRECOVERYQ 19$9.50+1.93%
- VTRSBUYViatris Inc.$20.4BBULLQ 5$17.54-0.57%
- AMRXBUYAmneal Pharmaceuticals, Inc.$6.4BBULLQ 15$20.03+0.60%
- BHCSELLBausch Health Companies Inc.$2.2BRECOVERYQ 2$5.93-1.82%
- ANIPSELLANI Pharmaceuticals, Inc.$1.7BRECOVERYQ 9$73.59-0.41%
- AMPHBUYAmphastar Pharmaceuticals, Inc.$1.2BRECOVERYQ 9$26.76+0.53%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on RDY?
- LOPJLB’s latest quantitative signal on Dr. Reddy's Laboratories Limited (RDY) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is RDY in?
- Dr. Reddy's Laboratories Limited (RDY) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Dr. Reddy's Laboratories Limited (RDY) do?
- Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under…